SG158149A1 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides - Google Patents
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptidesInfo
- Publication number
- SG158149A1 SG158149A1 SG200908440-1A SG2009084401A SG158149A1 SG 158149 A1 SG158149 A1 SG 158149A1 SG 2009084401 A SG2009084401 A SG 2009084401A SG 158149 A1 SG158149 A1 SG 158149A1
- Authority
- SG
- Singapore
- Prior art keywords
- natural amino
- polypeptides
- amino acids
- amino acid
- methods
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 9
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000004989 dicarbonyl group Chemical group 0.000 abstract 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract 2
- 150000002923 oximes Chemical class 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63852704P | 2004-12-22 | 2004-12-22 | |
US63841804P | 2004-12-22 | 2004-12-22 | |
US63919504P | 2004-12-22 | 2004-12-22 | |
US69621005P | 2005-07-01 | 2005-07-01 | |
US69630205P | 2005-07-01 | 2005-07-01 | |
US69606805P | 2005-07-01 | 2005-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG158149A1 true SG158149A1 (en) | 2010-01-29 |
Family
ID=36602327
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200908439-3A SG158148A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
SG200908678-6A SG158186A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
SG200908440-1A SG158149A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200908439-3A SG158148A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
SG200908678-6A SG158186A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
Country Status (16)
Country | Link |
---|---|
US (20) | US7385028B2 (fr) |
EP (2) | EP2399893B1 (fr) |
JP (1) | JP5425398B2 (fr) |
KR (1) | KR101423769B1 (fr) |
CN (1) | CN104803865A (fr) |
AU (2) | AU2005319125A1 (fr) |
BR (1) | BRPI0516385B1 (fr) |
CA (3) | CA2927595C (fr) |
DK (2) | DK1828224T3 (fr) |
GB (1) | GB2438982A (fr) |
HK (1) | HK1111702A1 (fr) |
IL (3) | IL183346A (fr) |
MX (1) | MX2007007590A (fr) |
NZ (1) | NZ555308A (fr) |
SG (3) | SG158148A1 (fr) |
WO (1) | WO2006069246A2 (fr) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US20220144872A1 (en) * | 2003-02-19 | 2022-05-12 | Panion & Bf Biotech Inc. | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same |
US20050287639A1 (en) | 2004-05-17 | 2005-12-29 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
JP2008517033A (ja) * | 2004-10-18 | 2008-05-22 | ノボ ノルディスク アクティーゼルスカブ | オキシム、チアゾリジン、ジチアン、ジチオランまたはヒドラゾンが連結した成長ホルモンの類似体の作製方法 |
US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
CN101107022B (zh) * | 2005-01-25 | 2013-07-17 | 辉瑞爱尔兰药品合伙公司 | 用于渗滤的方法 |
JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのFc標識化 |
PL1954710T3 (pl) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie |
US20080317670A1 (en) * | 2005-12-14 | 2008-12-25 | Ambrx, Inc. | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides |
SI1986612T1 (sl) | 2006-02-07 | 2013-01-31 | Shire Human Genetic Therapies, Inc. | Stabilizirana spojina glukocerebrosidaze |
JP5808882B2 (ja) | 2006-03-03 | 2015-11-10 | カリフォルニア インスティテュート オブ テクノロジー | 分子へのアミノ酸の部位特異的な組み込み |
US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
US8114844B2 (en) * | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
US7964181B2 (en) * | 2006-03-30 | 2011-06-21 | Palatin Technologies, Inc. | Amino acid surrogates for peptidic constructs |
EP2069396B1 (fr) | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations |
WO2008049034A1 (fr) * | 2006-10-17 | 2008-04-24 | Zymera, Inc. | Système permettant des dosages de l'aminotransférase |
EP2099475B1 (fr) * | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Administration sous-cutanée de polypeptides liés au facteur viia de la coagulation |
CN104163864B (zh) * | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
AU2008247815B2 (en) | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US20110178029A1 (en) * | 2007-09-14 | 2011-07-21 | Ambrx, Inc. | Modified Human Apolipoprotein A-1 and Their Uses |
MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
CN105647824A (zh) | 2007-12-11 | 2016-06-08 | 斯克利普斯研究院 | 甲基营养酵母菌巴斯德毕赤酵母中的体内非天然氨基酸表达 |
WO2009089542A2 (fr) | 2008-01-11 | 2009-07-16 | Serina Therapeutics, Inc. | Formes multifonctionnelles de copolymères de polyoxazoline et compositions médicamenteuses comprenant celles-ci |
US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
CN101939443B (zh) * | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
DE102008002209A1 (de) * | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Aufreinigung von Erythropoietin |
PT2318029T (pt) | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
JP5959201B2 (ja) | 2008-12-10 | 2016-08-02 | ザ スクリプス リサーチ インスティテュート | 化学的に反応性の非天然アミノ酸を使用するキャリア−ペプチド接合体の製造 |
US20090197339A1 (en) * | 2008-12-10 | 2009-08-06 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris |
WO2010096394A2 (fr) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation |
JP2012520326A (ja) * | 2009-03-13 | 2012-09-06 | アエロヴァンス インコーポレイティッド | 組換えタンパク質の再生法 |
DE102009015347A1 (de) * | 2009-03-27 | 2010-09-30 | Man Nutzfahrzeuge Aktiengesellschaft | Dieselkraftstoff auf Ethanol-Basis |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
CN102686237B (zh) | 2009-07-28 | 2018-10-19 | 夏尔人类遗传性治疗公司 | 用于治疗戈谢病的组合物 |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
WO2011044255A1 (fr) * | 2009-10-06 | 2011-04-14 | The Ohio State University | Analogues de pyrrolysine |
US20120283171A1 (en) | 2009-12-21 | 2012-11-08 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
SG181769A1 (en) | 2009-12-21 | 2012-07-30 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
US20110160143A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Psoriasis Compositions |
CA2787940C (fr) | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Agents polypeptidiques techniques pour la neutralisation de la grippe a large spectre ciblee |
JP5794558B2 (ja) * | 2010-03-24 | 2015-10-14 | 国立研究開発法人産業技術総合研究所 | 改変された致死遺伝子及び該遺伝子を含むベクター |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
PL2605789T3 (pl) | 2010-08-17 | 2019-11-29 | Ambrx Inc | Zmodyfikowane polipeptydy relaksyny i ich zastosowania |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
KR102025442B1 (ko) | 2010-12-22 | 2019-09-25 | 박스알타 인코퍼레이티드 | 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법 |
KR20140016262A (ko) | 2011-01-14 | 2014-02-07 | 레드우드 바이오사이언스 인코포레이티드 | 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법 |
JP2013199466A (ja) * | 2012-02-24 | 2013-10-03 | Fujifilm Corp | リコピン含有組成物 |
US20150018530A1 (en) * | 2012-02-29 | 2015-01-15 | Ambrx, Inc. | Novel Prodrug Containing Molecule Compositions and Their Uses |
CN104519905A (zh) | 2012-03-02 | 2015-04-15 | 夏尔人类遗传性治疗公司 | 用于治疗iii型戈谢病的组合物和方法 |
CA2871160C (fr) | 2012-05-10 | 2023-03-14 | Massachusetts Institute Of Technology | Agents convenant a la neutralisation de la grippe |
EP3536700A1 (fr) | 2012-06-07 | 2019-09-11 | Ambrx, Inc. | Conjugués anticorps-médicament d'antigène membranaire spécifique à la prostate |
SI2859017T1 (sl) | 2012-06-08 | 2019-05-31 | Sutro Biopharma, Inc. | Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe |
AU2013277169B2 (en) | 2012-06-19 | 2017-02-02 | Ambrx, Inc. | Anti-CD70 antibody drug conjugates |
WO2014004639A1 (fr) * | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Protéines de fc modifiées, comprenant des résidus d'acides aminés non naturels spécifiques de site, leurs conjugués, leur préparation et leurs procédés d'utilisation |
GB201211353D0 (en) | 2012-06-26 | 2012-08-08 | Cm Online Ltd | Interactive video |
ES2907763T3 (es) | 2012-08-31 | 2022-04-26 | Sutro Biopharma Inc | Aminoácidos modificados que comprenden un grupo azido |
CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
US10233249B2 (en) | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
EP3019522B1 (fr) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
US10910085B2 (en) | 2014-10-28 | 2021-02-02 | President And Fellows Of Harvard College | Methods of making polypeptides with non-standard amino acids using genomically recoded organisms |
WO2016073894A1 (fr) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Agents thérapeutiques avec une rétention oculaire accrue |
KR20230144660A (ko) | 2014-12-04 | 2023-10-16 | 셀진 코포레이션 | 생체분자 컨쥬게이트 |
WO2016159203A1 (fr) | 2015-03-31 | 2016-10-06 | 栄研化学株式会社 | Solution de conservation de la protéine héminique, et procédé de stabilisation de protéine héminique |
EP3283508B1 (fr) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Protéines immunomodulatrices à affinités accordables |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
SG11201806419RA (en) | 2016-01-27 | 2018-08-30 | Sutro Biopharma Inc | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
WO2017161183A1 (fr) | 2016-03-16 | 2017-09-21 | The Regents Of The University Of California | Liants peptidiques covalents |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
WO2018156801A2 (fr) | 2017-02-22 | 2018-08-30 | Bioincept, Llc | Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant |
IL270179B2 (en) | 2017-04-25 | 2024-07-01 | Temple Otorongo Llc | A pharmaceutical preparation containing tryptophan and a phyllokinin derivative for the treatment of psychiatric and psychological disorders |
JP7002788B2 (ja) * | 2017-07-05 | 2022-03-03 | 拜西欧斯(北京)生物技術有限公司 | ポリペプチドの薬学的に許容される塩およびその使用 |
EP3655010A4 (fr) | 2017-07-17 | 2021-06-09 | Bioincept LLC | Peptides et procédés de transplantation et de restauration de fonction d'organe |
CA3093377A1 (fr) * | 2018-03-08 | 2019-09-12 | The Regents Of The University Of California | Compositions bioreactives et leurs procedes d'utilisation |
CN108538399A (zh) * | 2018-03-22 | 2018-09-14 | 复旦大学 | 一种磁共振肝癌疗效评估方法和系统 |
CA3093083A1 (fr) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugues |
CA3093722A1 (fr) | 2018-03-28 | 2019-10-03 | Ascendis Pharma Oncology Division A/S | Conjugues d'il-2 |
WO2019241438A2 (fr) * | 2018-06-12 | 2019-12-19 | Promega Corporation | Luciférase multipartite |
CN110760306B (zh) * | 2018-07-27 | 2021-11-23 | Tcl科技集团股份有限公司 | 一种量子点的提纯方法 |
BR112021003843A2 (pt) | 2018-08-28 | 2021-05-25 | Ambrx, Inc. | biconjugados de folato de anticorpo anti-cd3 e seus usos |
US20210356377A1 (en) * | 2018-09-07 | 2021-11-18 | Medimmune, Llc | Methods Of Cell Selection |
CA3111576A1 (fr) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Conjugues polypeptidiques d'interleukine-2 et leurs utilisations |
AU2019361206A1 (en) | 2018-10-19 | 2021-06-03 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
KR20210136014A (ko) | 2019-02-12 | 2021-11-16 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도 |
CA3130693A1 (fr) | 2019-02-19 | 2020-08-27 | Ultima Genomics, Inc. | Lieurs et procedes de detection et de sequencage optiques |
IL289458A (en) | 2019-06-29 | 2022-07-01 | Hangzhou Dac Biotech Co Ltd | A cell-binding conjugated derivative of the tubolisin molecule and a method for its production |
CN113179631B (zh) * | 2019-11-25 | 2024-08-30 | 中国科学院理化技术研究所杭州研究院 | 通过临近使能反应疗法开发的共价蛋白质药物 |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
WO2021173889A1 (fr) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Utilisations de bioconjugués folate-anticorps anti-cd3 |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
WO2021215428A1 (fr) * | 2020-04-22 | 2021-10-28 | 日華化学株式会社 | Procédé de détection d'acide nucléique et sonde oligonucléotide |
CN112028987B (zh) * | 2020-06-01 | 2021-07-30 | 广东圣赛生物科技有限公司 | 一种结合免疫抑制分子pd-l1的蛋白药物 |
CA3178074A1 (fr) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Sequences d'il-2 et leurs utilisations |
CN116419767A (zh) * | 2020-08-18 | 2023-07-11 | 阿尔缇玛基因组学公司 | 用于标记生物分子的试剂 |
JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲート、その方法及び使用 |
WO2022194078A1 (fr) * | 2021-03-15 | 2022-09-22 | 北京大学 | Conjugué pour modification de molécule cible et son procédé de préparation |
EP4313163A1 (fr) | 2021-04-03 | 2024-02-07 | Ambrx, Inc. | Conjugués anticorps-médicament anti-her2 et leurs utilisations |
WO2022232377A2 (fr) * | 2021-04-28 | 2022-11-03 | The Regents Of The University Of California | Protéines bioréactives contenant des acides aminés non naturels |
AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
EP4366781A1 (fr) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Inhibiteurs de points de contrôle conjugués à il-2, et leurs utilisations |
CA3222357A1 (fr) | 2021-07-09 | 2023-01-12 | Bertolt Kreft | Polypeptides il-2 modifies pour le traitement de maladies inflammatoires et auto-immunes |
WO2023281482A1 (fr) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Il-2 ciblant cd20 et ses utilisations |
CA3224147A1 (fr) | 2021-07-09 | 2023-01-12 | Vijaya Raghavan PATTABIRAMAN | Conjugues d'anticorps et leur fabrication |
US20230355795A1 (en) | 2022-02-23 | 2023-11-09 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
WO2023161857A1 (fr) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Compositions de cytokine bifonctionnelle |
WO2024077277A1 (fr) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Lieurs de médicaments et conjugués d'anticorps associés |
KR102526689B1 (ko) * | 2022-11-24 | 2023-04-28 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드-4를 포함하는 액정수화 화장료 조성물 |
KR102524528B1 (ko) * | 2022-11-24 | 2023-04-21 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드의 제조방법 |
WO2024150174A1 (fr) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Immunocytokines activées de manière conditionnelle et procédés d'utilisation |
WO2024150158A1 (fr) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Polypeptides il-7, immunocytokines les comprenant et leurs utilisations |
WO2024150175A1 (fr) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Protéines activées de manière conditionnelle et procédés d'utilisation |
WO2024155627A1 (fr) | 2023-01-16 | 2024-07-25 | Ambrx, Inc. | Conjugués anticorps-médicament anti-cd70 |
WO2024178310A1 (fr) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Conjugués anticorps-médicament dirigés contre trop2 et utilisations associées |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644281A (en) * | 1899-12-01 | 1900-02-27 | Samuel Crump | Process of drying and varnishing prints. |
US3849576A (en) * | 1964-01-29 | 1974-11-19 | Oreal | Process and cosmetic compositions for the treatment of skin and scalp |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB1366554A (en) | 1972-03-06 | 1974-09-11 | Science Union & Cie | Phenylalanine derivatives and a process for their preparation |
US4272432A (en) * | 1974-11-13 | 1981-06-09 | American Home Products Corporation | Claudogenic-interceptive nonapeptide |
ZA783356B (en) * | 1977-07-21 | 1979-06-27 | Merrell Toraude & Co | A-halomethyl amino acid derivatives |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
DE3043159C2 (de) * | 1980-11-15 | 1982-12-09 | Degussa Ag, 6000 Frankfurt | Cyclische Acetale des Glutaminsäure-γ-semialdehyds, Verfahren zu deren Herstellung und ihre Verwendung |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
US4512922A (en) | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4820352A (en) | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
US5089398A (en) | 1983-02-22 | 1992-02-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid GAPDH promoter region constructs |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
CA1341116C (fr) | 1983-02-22 | 2000-10-17 | Rae Lyn Burke | Systemes d'expression de la levure avec des vecteurs ayant des promoteurs de gapdh ou pyk, et synthese de proteine etrangere |
JPS59166086A (ja) | 1983-03-09 | 1984-09-19 | Teruhiko Beppu | 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法 |
IE58011B1 (en) | 1983-05-27 | 1993-06-16 | Texas A & M Univ Sys | Method for producing a recombinant baculovirus expression vector |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
EP0164556B1 (fr) | 1984-05-11 | 1994-03-02 | Chiron Corporation | Transcription augmentée dans les levures par usage d'une construction hybride de la région du promoteur |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
DE3680924D1 (de) | 1985-01-14 | 1991-09-26 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
JPS61243018A (ja) * | 1985-04-18 | 1986-10-29 | Taisho Pharmaceut Co Ltd | 真菌症治療剤 |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5186933A (en) | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
WO1988007082A1 (fr) | 1987-03-16 | 1988-09-22 | American Biogenetic Sciences, Inc. | Corps d'occlusion formes par des bacillovirus recombinants et utilises dans des vaccins et comme insecticides biologiques |
JP2795850B2 (ja) | 1987-03-23 | 1998-09-10 | ザイモジェネティクス,インコーポレイティド | 酵母発現ベクター |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
AU2251488A (en) | 1987-07-24 | 1989-03-01 | Cetus Corporation | Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system |
AU2136788A (en) | 1987-07-24 | 1989-03-01 | Cetus Corporation | Production of ricin toxins in a baculovirus-insect cell expression system |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
CN1049686C (zh) | 1987-11-18 | 2000-02-23 | 希龙股份有限公司 | 非a和非b肝炎病毒的诊断及疫苗 |
CA1340772C (fr) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha |
JP2801322B2 (ja) | 1988-01-13 | 1998-09-21 | インスティチュート・パスツール | 溶血性リステリア属に特異的なdnaプローブ |
CA1324969C (fr) | 1988-05-06 | 1993-12-07 | Jeffrey R. Shuster | Expression a haut rendement de proteines dans la levure |
US5674706A (en) | 1988-05-06 | 1997-10-07 | Chiron Corporation | High level expression of proteins in yeast |
FR2631974B1 (fr) | 1988-05-31 | 1992-12-11 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes |
AU4197389A (en) | 1988-08-05 | 1990-03-05 | Mount Sinai School Of Medicine Of The City University Of New York, The | In vivo infection of live insects with a recombinant baculovirus |
GB8819453D0 (en) | 1988-08-16 | 1988-09-21 | Roy P | Production of bluetongue virus non-structural proteins using baculovirus expression vector |
NZ230425A (en) | 1988-09-02 | 1992-07-28 | Molecular Eng Ass | Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector |
JPH04504651A (ja) | 1988-11-18 | 1992-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 自然に存在しないアミノ酸をタンパク質に部位特異的に導入する方法 |
WO1990010078A1 (fr) | 1989-02-23 | 1990-09-07 | University Of Ottawa | Systeme ameliore d'expression de baculovirus capable de produire des proteines de genes etrangers en grande quantite |
WO1990010277A1 (fr) | 1989-02-24 | 1990-09-07 | Cell Analysis Systems, Inc. | Procede et dispositif pour determiner un indice de proliferation dans un echantillon cellulaire |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DK0470128T4 (da) | 1989-04-19 | 2003-12-01 | Enzon Inc | Aktive polyalkylenoxidcarbonater til modifikation af polypeptider |
JPH04501065A (ja) | 1989-05-17 | 1992-02-27 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション インコーポレイテッド | 改良されたバキュロウイルス発現ベクター |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
CA2018801C (fr) * | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Derives peptidiques comprenant une terminaison-n1,4-dioxo-c4 |
FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
WO1992001800A1 (fr) | 1990-07-20 | 1992-02-06 | Chiron Corporation | Procede de transformation integrante de levure au moyen d'elements repetitifs disperses |
FR2665923B1 (fr) | 1990-08-14 | 1993-01-22 | Arbona Jean | Unite de soins modulaire. |
CA2090969C (fr) | 1990-09-04 | 2001-08-21 | Russell Arthur Brierley | Production de facteur de croissance insulinoide dans les cellules de levure methylotrophiques |
IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5231178A (en) | 1991-01-16 | 1993-07-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Method for the purification of intact, correctly-folded insulin-like growth factor-1 |
AU1651992A (en) | 1991-03-19 | 1992-10-21 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Expression of influenza nucleoprotein antigens in baculovirus |
US6126944A (en) | 1991-04-26 | 2000-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5290686A (en) | 1991-07-31 | 1994-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Expression of influenza a M2 protein in baculovirus |
IT1260468B (it) | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
JPH07505915A (ja) | 1992-04-14 | 1995-06-29 | コーネル リサーチ ファウンデーション、インコーポレーテッド | 樹枝状巨大分子およびその製造法 |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
WO1994004193A1 (fr) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Nouvelle fixation d'oxydes de polyalkylene a des substances presentant une efficacite biologique |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
CA2110543A1 (fr) * | 1992-12-09 | 1994-06-10 | David E. Wright | Reactifs formant des chainons peg-hydrazone et peg-oxyme et derives proteiniques ainsi obtenus |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5464820A (en) * | 1993-06-22 | 1995-11-07 | The University Hospital | Specific inhibitors of tissue kallikrein |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
DE4335555A1 (de) | 1993-10-19 | 1995-04-20 | Basf Ag | Oximether und diese enthaltende Copolymerisate |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605792A (en) | 1993-11-04 | 1997-02-25 | The Ohio State University Research Foundation | Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
FR2715664B1 (fr) | 1994-01-31 | 1996-04-12 | Proteine Performance Sa | Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux. |
JP3090586B2 (ja) | 1994-03-15 | 2000-09-25 | 片倉工業株式会社 | システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法 |
US6403375B1 (en) | 1994-08-24 | 2002-06-11 | Boyce Thompson Institute For Plant Research, Inc. | Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996041813A2 (fr) | 1994-11-09 | 1996-12-27 | Offord Robin E | Polymeres fonctionnalises destines a une ligation dirigee |
IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6183987B1 (en) | 1995-02-17 | 2001-02-06 | Stichting Institut Voor Dierhouderij En Diergezonheld | Production of biologically active recombinant bovine follicle stimulation hormone (rec bFSH) in the baculovirus expression system |
FR2732035B1 (fr) | 1995-03-23 | 1997-05-30 | Agronomique Inst Nat Rech | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede |
US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
NZ308772A (en) | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
JPH09157578A (ja) * | 1995-12-08 | 1997-06-17 | Daikin Ind Ltd | 含フッ素塗料用材料およびそれを用いた被覆方法 |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
AU1690697A (en) | 1996-01-17 | 1997-08-11 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists |
US5861279A (en) | 1996-01-17 | 1999-01-19 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
US5876916A (en) * | 1996-03-18 | 1999-03-02 | Case Western Reserve University | Pyruvate compounds and methods for use thereof |
AU3908597A (en) * | 1996-08-02 | 1998-02-25 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
EP1365028B1 (fr) | 1996-12-13 | 2009-03-18 | Novartis Vaccines and Diagnostics, Inc. | Procédés permettant d'exprimer des protéines PDGF ou IGF dans la levure |
GB9703406D0 (en) | 1997-02-19 | 1997-04-09 | Chiron Spa | Expression of heterologous proteins |
US6399337B1 (en) | 1997-06-06 | 2002-06-04 | The Governors Of The University Of Alberta | α1,3-fucosyltransferase |
US5965393A (en) | 1997-07-01 | 1999-10-12 | National Institute Of Immunology | Method for enhancing foreign gene expression in baculovirus expression vector system |
ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
GB9715660D0 (en) | 1997-07-25 | 1997-10-01 | Zeneca Ltd | Proteins |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
JP2001512684A (ja) | 1997-08-05 | 2001-08-28 | カイロン コーポレイション | 新規のpichiapastoris遺伝子配列およびそれらの使用方法 |
DE19735593C2 (de) | 1997-08-15 | 1999-08-26 | Hepavec Ag Fuer Gentherapie | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
US6090584A (en) | 1997-08-21 | 2000-07-18 | University Technologies International Inc. | Baculovirus artificial chromosomes and methods of use |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
US6449281B1 (en) * | 1997-09-30 | 2002-09-10 | Intel Corporation | Interface control of communication between a control processor and a digital signal processor |
JPH11140076A (ja) * | 1997-11-04 | 1999-05-25 | Dai Ichi Pure Chem Co Ltd | N−アシル−α−アミノアジピン酸−γ−セミアルデヒドエチレンアセタール |
EP0924298A1 (fr) | 1997-12-18 | 1999-06-23 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Expression de proteine dans des systèmes d'expression faisant appel aux baculovirus |
AU2898299A (en) | 1998-03-04 | 1999-09-20 | Onyx Pharmaceuticals, Inc. | Baculovirus expression system and method for high throughput expression of genetic material |
EP1062230B1 (fr) | 1998-03-05 | 2004-10-13 | Chiron Corporation | Procede d'augmentation de la demi-vie serique d'une molecule biologiquement active |
DE69920670T2 (de) * | 1998-03-11 | 2006-02-16 | G.D. Searle & Co., Chicago | Halogenierte aminosäure derivate als hemmstoffe der stickstoffmonoxid-synthase |
KR100264953B1 (ko) | 1998-04-03 | 2001-03-02 | 박현우 | 재조합 베큘로바이러스, 이의 제조방법 및 이를 포함하는 미생물 살충제 |
US6168932B1 (en) | 1998-07-13 | 2001-01-02 | Parker Hughes Institute | Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system |
US6245528B1 (en) | 1998-07-28 | 2001-06-12 | Academia Sinica | Latent baculovirus expression system |
US6368825B1 (en) | 1998-08-10 | 2002-04-09 | Academia Sinica | Baculovirus containing minimal CMV promoter |
AU6059699A (en) * | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
WO2000020032A1 (fr) | 1998-10-06 | 2000-04-13 | Trustees Of Dartmouth College | ALLERGENE RECOMBINANT DU CHAT, Fel dI, EXPRIMES DANS BACULOVIRUS POUR DIAGNOSTIQUER OU TRAITER L'ALLERGIE AUX CHATS |
CA2365668C (fr) | 1999-03-17 | 2014-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | Techniques de biosynthese macromoleculaire in vitro utilisant des acides amines exogenes et un nouveau systeme pour la generation d'atp |
US6994986B2 (en) | 1999-03-17 | 2006-02-07 | The Board Of Trustees Of The Leland Stanford University | In vitro synthesis of polypeptides by optimizing amino acid metabolism |
US6342216B1 (en) | 1999-03-17 | 2002-01-29 | The Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
US6337191B1 (en) * | 1999-03-22 | 2002-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Vitro protein synthesis using glycolytic intermediates as an energy source |
US6312725B1 (en) * | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6261805B1 (en) | 1999-07-15 | 2001-07-17 | Boyce Thompson Institute For Plant Research, Inc. | Sialyiation of N-linked glycoproteins in the baculovirus expression vector system |
AU2039501A (en) | 1999-10-15 | 2001-04-23 | Rockefeller University, The | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
GB9929613D0 (en) * | 1999-12-15 | 2000-02-09 | Koninkl Philips Electronics Nv | Manufacture of semiconductor material and devices using that material |
SE0000055D0 (sv) * | 2000-01-10 | 2000-01-10 | Centaur Pharmaceuticals Inc | Novel process |
GB0012997D0 (en) | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP2002030098A (ja) | 2000-07-17 | 2002-01-29 | Institute Of Immunology Co Ltd | バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法 |
JP2004508338A (ja) | 2000-09-08 | 2004-03-18 | グリフォン セラピューティクス,インコーポレーテッド | ポリマー修飾合成タンパク質 |
MXPA03009566A (es) | 2001-04-19 | 2004-12-06 | Scripps Research Inst | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
US6608196B2 (en) * | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
ATE408593T1 (de) * | 2001-05-03 | 2008-10-15 | Galileo Lab Inc | Pyruvatderivate |
GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
US20030154058A1 (en) * | 2001-06-11 | 2003-08-14 | Keener Bryan F. | Methods and systems for validating translated geometry |
US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
WO2003022261A1 (fr) * | 2001-09-13 | 2003-03-20 | Miller Kenneth E | Methode pour soulager la douleur |
MXPA04004336A (es) | 2001-11-07 | 2005-05-16 | Nektar Therapeutics Al Corp | Polimeros ramificados y sus conjugados. |
US7884182B2 (en) | 2001-11-14 | 2011-02-08 | Amylin Pharmaceuticals, Inc. | Chemical peptide ligation with three or more components |
BR0214451A (pt) * | 2001-11-20 | 2006-05-30 | Pharmacia Corp | conjugados do hormÈnio do crescimento humano quimicamente modificado |
MXPA05003983A (es) | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Incorporacion en sitio especifico de cetoaminoacidos en proteinas. |
US7642085B2 (en) | 2002-12-22 | 2010-01-05 | The Scripps Research Institute | Protein arrays |
WO2004060966A2 (fr) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Derives polymeres d'acides maleamiques et leurs bioconjugues |
WO2004072243A2 (fr) * | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la serine protease de l'hepatite c |
CA2520750A1 (fr) | 2003-04-17 | 2004-11-04 | The Scripps Research Institute | Extension du code genetique eucaryote |
US20090297561A1 (en) * | 2003-09-03 | 2009-12-03 | Intralytix | Method for vaccination of poultry by bacteriophage lysate bacterin |
KR20070090023A (ko) * | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
US7385028B2 (en) * | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
JP4478883B2 (ja) * | 2005-03-25 | 2010-06-09 | ヤマハ株式会社 | 音楽再生装置およびプログラム |
DE102005036719A1 (de) * | 2005-07-28 | 2007-02-01 | Carl Zeiss Industrielle Messtechnik Gmbh | Verfahren zum Korrigieren von Interpolationsfehlern einer Maschine, insbesondere eines Koordinatenmessgerätes |
PL1954710T3 (pl) | 2005-11-08 | 2011-09-30 | Ambrx Inc | Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie |
US20080317670A1 (en) | 2005-12-14 | 2008-12-25 | Ambrx, Inc. | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides |
EP1978989A4 (fr) | 2005-12-30 | 2009-03-18 | Ambrx Inc | Acides aminés et polypeptides non naturels, compositions contenant ceux-ci, procédés mettant en jeu ceux-ci et utilisations de ceux-ci |
US7760037B2 (en) * | 2007-03-28 | 2010-07-20 | Intel Corporation | Process, voltage, and temperature compensated clock generator |
US20090113333A1 (en) | 2007-10-26 | 2009-04-30 | Palm, Inc. | Extendable Toolbar for Navigation and Execution of Operational Functions |
-
2005
- 2005-12-21 US US11/313,956 patent/US7385028B2/en active Active
- 2005-12-21 EP EP11177567.2A patent/EP2399893B1/fr active Active
- 2005-12-21 US US11/313,306 patent/US7332571B2/en active Active
- 2005-12-21 WO PCT/US2005/046618 patent/WO2006069246A2/fr active Application Filing
- 2005-12-21 US US11/313,305 patent/US7638491B2/en active Active
- 2005-12-21 GB GB0713066A patent/GB2438982A/en not_active Withdrawn
- 2005-12-21 CA CA2927595A patent/CA2927595C/fr active Active
- 2005-12-21 BR BRPI0516385-4A patent/BRPI0516385B1/pt active IP Right Grant
- 2005-12-21 SG SG200908439-3A patent/SG158148A1/en unknown
- 2005-12-21 CA CA2590590A patent/CA2590590C/fr active Active
- 2005-12-21 CN CN201510093838.4A patent/CN104803865A/zh active Pending
- 2005-12-21 DK DK05855215.9T patent/DK1828224T3/en active
- 2005-12-21 SG SG200908678-6A patent/SG158186A1/en unknown
- 2005-12-21 DK DK11177567.2T patent/DK2399893T3/en active
- 2005-12-21 KR KR1020077016540A patent/KR101423769B1/ko active IP Right Grant
- 2005-12-21 NZ NZ555308A patent/NZ555308A/en unknown
- 2005-12-21 JP JP2007548475A patent/JP5425398B2/ja active Active
- 2005-12-21 MX MX2007007590A patent/MX2007007590A/es active IP Right Grant
- 2005-12-21 EP EP05855215.9A patent/EP1828224B1/fr active Active
- 2005-12-21 CA CA3005835A patent/CA3005835C/fr active Active
- 2005-12-21 AU AU2005319125A patent/AU2005319125A1/en not_active Abandoned
- 2005-12-21 SG SG200908440-1A patent/SG158149A1/en unknown
-
2007
- 2007-05-21 IL IL183346A patent/IL183346A/en active IP Right Grant
- 2007-10-16 US US11/873,347 patent/US7928163B2/en active Active
- 2007-10-17 US US11/874,060 patent/US7696312B2/en active Active
- 2007-10-17 US US11/874,094 patent/US20080177038A1/en not_active Abandoned
- 2007-10-18 US US11/874,486 patent/US20080213840A1/en not_active Abandoned
- 2007-10-26 US US11/925,699 patent/US20080268519A1/en not_active Abandoned
- 2007-10-26 US US11/925,662 patent/US20080268518A1/en not_active Abandoned
- 2007-10-26 US US11/925,743 patent/US20090111147A1/en not_active Abandoned
- 2007-12-07 US US11/952,960 patent/US8008456B2/en active Active
- 2007-12-07 US US11/952,975 patent/US8048988B2/en active Active
-
2008
- 2008-02-06 US US12/027,130 patent/US8263740B2/en active Active
- 2008-03-04 HK HK08102427.1A patent/HK1111702A1/zh unknown
-
2009
- 2009-11-05 US US12/613,423 patent/US8367612B2/en active Active
-
2010
- 2010-10-06 AU AU2010226982A patent/AU2010226982B2/en active Active
-
2011
- 2011-01-13 US US13/006,335 patent/US8809511B2/en active Active
- 2011-01-13 US US13/006,361 patent/US8791231B2/en active Active
- 2011-01-13 US US13/006,350 patent/US8859802B2/en active Active
- 2011-07-07 US US13/178,189 patent/US8476411B2/en active Active
-
2012
- 2012-06-20 US US13/528,723 patent/US8846876B2/en active Active
- 2012-07-03 IL IL220740A patent/IL220740A/en active IP Right Grant
-
2013
- 2013-08-01 IL IL227753A patent/IL227753A/en active IP Right Grant
-
2014
- 2014-05-29 US US14/290,797 patent/US9637441B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG158148A1 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
WO2007079130A3 (fr) | Acides aminés et polypeptides non naturels, compositions contenant ceux-ci, procédés mettant en jeu ceux-ci et utilisations de ceux-ci | |
WO2011028195A3 (fr) | Compositions contenant et procédés faisant intervenir des acides aminés et polypeptides non naturels et utilisations de ceux-ci | |
SG170116A1 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
MX2021009644A (es) | Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr. | |
MX2020001231A (es) | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. | |
WO2007059312A3 (fr) | Procedes et compositions comprenant des acides amines non naturels | |
MX2009007001A (es) | Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. | |
EP2581450A3 (fr) | Polypeptides à substitution d'acide aminé non naturel | |
WO2005119251A3 (fr) | Nouveaux dispositifs et procedes de traitement de la perte d'audition et des acouphenes | |
WO2006087550A3 (fr) | Peptides fixant les amyloides, produits analogues et applications de ces peptides | |
WO2005077042A3 (fr) | Proteines hybrides d'albumine | |
WO2007002261A3 (fr) | Anticorps bloquant il-1$g(b) et leurs fragments | |
EP2284192A3 (fr) | Anticorps de Camelidae pour administration sublinguale | |
WO2005003296A3 (fr) | Proteines hybrides d'albumine | |
WO2007021494A3 (fr) | Proteines de fusion avec l'albumine | |
WO2007056448A3 (fr) | Accelerateurs destines a la modification d’acides amines non-naturels et de polypeptides formes d'acides amines non-naturels | |
EP2631242A3 (fr) | Procédé pour la concentration d'un polypeptide | |
WO2007149542A3 (fr) | Compositions de chémokine microbicide antimicrobiennes et procédés d'utilisation | |
TWI365867B (en) | Process for preparing cyclohexanone and cyclohexanol | |
WO2004048517A3 (fr) | Procede pour reduire ou prevenir la modification d'un peptide dans une solution | |
WO2004053059A3 (fr) | Polypeptide de « mitoneet » provenant de membranes mitochondriales, modulateurs correspondants, et leurs methodes d'utilisation | |
DE60142239D1 (de) | DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE | |
WO2007093848A3 (fr) | Nouveaux polypeptides purifiés issus de helicobacter pylori | |
WO2005059131A3 (fr) | Proteine fixant des proteines en miniature et leurs applications |